Healthcare / Medical Instruments & SuppliesTokyo
$8000.00
-110.00 (-1.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $5.1B · quality 70.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$186.8B
P/E
23.5x
↑EV/EBITDA
12.3x
↑ROE
26.2%
↑Gross Margin
78.0%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.3%
FCF CAGR
+62.8%
FCF margin
5.2%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $97.22B · net income $8.33B · FCF $5.10B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $97.22B | $97.22B | $83.00B | $73.26B | $66.90B |
| Net Income | $8.33B | $8.33B | $4.67B | $1.76B | $750.0M |
| EBITDA | $14.73B | $14.73B | $10.26B | $5.94B | $5.20B |
| EPS | — | — | 190.97 | 69.42 | 27.37 |
| Gross Margin | 78.0% | 78.0% | 77.6% | 76.8% | 77.9% |
| Operating Margin | 12.4% | 12.4% | 9.4% | 6.6% | 5.0% |
| Net Margin | 8.6% | 8.6% | 5.6% | 2.4% | 1.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.48 | 0.57 | 1.12 |
| Current Ratio | 1.25 | 1.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.10B | $5.10B | $8.36B | $2.46B | $1.18B |
| Returns | |||||
| ROE | 26.2% | 26.2% | 18.3% | 8.1% | 3.7% |
| Valuation | |||||
| P/E | 23.54 | 23.54 | 27.12 | 49.63 | 148.52 |
| EV/EBITDA | 12.25 | 12.25 | 11.74 | 14.77 | 21.67 |
| P/B | 5.88 | 5.88 | 4.95 | 4.02 | 5.46 |
| Growth & Yield | |||||
| Revenue Growth | 17.1% | 17.1% | 13.3% | 9.5% | — |
| EPS Growth | — | — | 175.1% | 153.6% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.5%
Start / end P/E
n/dx → n/dx
EPS bridge
190.97 → n/d
Residual
-8.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.